It is now apparent that adiponectin resistance most commonly develops in obesity, diabetes and heart failure, when it is accompanied by decreased receptors expression, reduced receptor sensitivity and impaired downstream signaling [212]. Here, ADIPOQ is linked to diabetes mellitus.